Binimetinib is a MEK inhibitor. It’s designed to target melanoma with BRAF V600E/K mutations. It works by blocking this MEK signaling.
That’s a pathway in melanoma cells related to cell growth and survival. These are 15 mg film-coated tablets. The usual dose is 45 mg taken twice a day.
Each package comes with a bottle of 84 tablets. You need to take it with encorafenib. It’s usually part of a combined therapy plan.
The film-coated tablets are easy to swallow and help make sure patients take the med as they should. It’s meant to be taken orally. This makes sure it’s absorbed evenly and works the whole time.
Binimetinib’s use is guided by specific dosing recommendations to optimize the balance between efficacy and potential side effects, making it a critical component in the treatment plan for patients with advanced melanoma.
